A Study to Evaluate the Safety and Feasibility of Irinotecan, Trifluridine/Tipiracil (TAS-102), and Oxaliplatin (iTTo) for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Irinotecan (Primary) ; Oxaliplatin (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- 13 Jun 2024 Status changed from not yet recruiting to completed.
- 25 Mar 2021 New trial record